|
 The Economic Times newspaper reported earlier on Tuesday that the
company would no longer undertake local trials for its vaccine,
after India's decision to scrap bridging clinical trials for
vaccines approved by regulators in other nations. (https://bit.ly/3h2x358)
J&J did not specify in its comment whether it has scrapped the
trial.
The U.S.-based company said in April it was seeking an approval to
conduct a bridging clinical study of its Janssen COVID-19 vaccine
candidate in India.
In late-May, however, the country scrapped local trials for
"well-established" vaccines manufactured in other countries.
[to top of second column] |
More than 41 million vaccine doses were administered across India in
just the last one week, at a time when experts have said that
widespread vaccination remains one of the best tools to avoid the
kind of devastation the country saw during the pandemic's second
wave.
(Reporting by Shivani Singh, Anuron Kumar Mitra and Juby Babu in
Bengaluru; Editing by Shounak Dasgupta and Uttaresh.V)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
